RADIKAL THERAPEUTICS, INC. — Department of Health and Human Services SBIR Phase II: Contrast media (CM) induced nephropathy (CIN) remains prevalent and debilitating, the thir
RADIKAL THERAPEUTICS, INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,527,261
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
Contrast media (CM) induced nephropathy (CIN) remains prevalent and debilitating, the third most common cause of acute renal failure. Based on more than 80 million (M) CM injections in the USA per annum, of which 10% take place in a population highly susceptible to the development of CIN, and a unit pricing of 200 per course, we estimate the total domestic potential market equals 1.6B. At present there is no meaningful competition for this market, either registered or in development. To meet this unmet medical need, Radikal Therapeutics is developing a first-in-class mitochondrial-selective K+-ATP channel opener that activates a major endogenous cytoprotective mechanism. In a rat model of CIN, R-801 administration reduced CM- induced elevation in serum creatinine by 85%, blocked the reduction in renal medullary blood flow, eliminated lipid peroxidation and peroxynitrite formation, abrogated activation of the nuclear cell death enzyme poly(ADP-ribose) polymerase, and reduced congestion and necrosis of the m